# A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

> **NCT01251653** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 94 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Afatinib
- **DRUG:** docetaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT01251653
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2016-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251653, "A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01251653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*